Eli Lilly To Shift To Commercial Sales Of Its Covid Antibody Drug


As government orders dry up, the sales of bebtelovimab, which is currently authorized for emergency use, will target states, hospitals, and other health care providers. CNN notes other shifts in government covid policy are happening, with the CDC expected to ease covid guidelines, including for schools.


The Wall Street Journal:
Eli Lilly’s Covid-19 Antibody Treatment To Be Sold Commercially


Eli Lilly & Co. said it plans to begin commercial sales of its Covid-19 monoclonal antibody treatment to states, hospitals and other healthcare providers this month, as the federal government’s supply of the drug is nearly depleted. The move marks a shift away from the way Lilly’s drug and most other Covid-19 treatments and vaccines have been distributed in the U.S. It will likely be the first test of whether the vaccines and treatments would remain accessible if shifted to a commercial market. (Armour and Loftus, 8/3)

In covid vaccine news —


CIDRAP:
Studies: 3 Or 4 COVID Vaccine Doses Protective Against Omicron


Three new studies show that recipients of three or four mRNA COVID-19 vaccine doses received substantially better protection against infection with the Omicron variant than those who received only two. … The rate of breakthrough infection was 7% in workers who received four vaccine doses, compared with 20% in the 4,802 of 24,280 participants who received only three. (Van Beusekom, 8/3)


This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.



Source link

Ozinize
Logo
Shopping cart